The current issue of the renowed magazine CHEManager International features a very interesting series of interviews on the topic "The Evolution of the CDMO Industry".

More than 25 executives and industry experts give their views on how their companies are addressing the current challenges.

In it, Aenova Chief Commercial Officer Neil Jones shares his view on the CDMO market and highlights three key aspects of an excellent partnership between customer and CDMO partner.

Aenova Chief Commercial Officer Neil Jones is among them and shares his view on the CDMO market and highlights three key aspects of an excellent partnership between customer and CDMO partner. Read more.

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Contract development and manufacturing organizations (CDMOs) have been on the rise in the last decade. Historically, CDMOs operated on a business model which predominantly focused on serving as external service providers for manufacturing pharmaceuticals. This model included the addition of capacity by the acquisition of manufacturing facilities from (bio)pharma companies or own capital investments. However, CDMOs have increasingly become innovation leaders and cover more areas of the pharma business, not just manufacturing, opening up additional revenue streams.

You can find the entire statement series here.